Clinical Trial Update: Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant cemiplimab (PD-1 inhibitor) for stage I–II Merkel cell carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II | Phase 2 | Status: NOT_YET_RECRUITING